<p>Compass Pathways PLC 贊助的 ADR（NASDAQ:CMPS - 獲取免費報告）在週四的交易中交易量強勁。當天交易了 7,108,036 股，較前一交易日的 2,787,246 股增加了 155%。該股票最後交易價格為 $7.9980，之前收盤價為 $8.45。</p>
<p>獲取 <strong>Compass Pathways</strong> 的提醒：</p>
<h2>分析師升級和降級</h2>
<ul>
<li>魔法蘑菇，現金：Compass Pathways 的試驗勝利，快速融資</li>
</ul>
<p>CMPS 已成為多份分析師報告的主題。Lifesci Capital 在 2 月 12 日的研究報告中將 Compass Pathways 的股票評級上調至 &#34;強力買入&#34;。Compass Point 在 2 月 12 日的研究報告中設定了 Compass Pathways 的目標價為 $15.00。摩根士丹利在週三的研究報告中將 Compass Pathways 的目標價從 $11.00 提升至 $18.00，並給予該股票 &#34;超配&#34; 的評級。Canaccord Genuity Group 在週三的報告中將 Compass Pathways 的目標價從 $15.00 提升至 $20.00，並給予該公司 &#34;買入&#34; 的評級。最後，Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Compass Pathways 股票的 &#34;賣出（d-）&#34; 評級。一位分析師給予該股票 &#34;強力買入&#34; 的評級，七位分析師給予 &#34;買入&#34; 評級，一位分析師給予 &#34;持有&#34; 評級，一位分析師給予 &#34;賣出&#34; 評級。根據 MarketBeat 的數據，該公司的共識評級為 &#34;適度買入&#34;，共識目標價為 $17.56。</p>
<p><strong>閲讀我們關於 CMPS 的最新報告</strong></p>
<h2>Compass Pathways 股價下跌 3.3%</h2>
<p>該公司的市值為 7.842 億美元，市盈率為 -3.01，貝塔係數為 1.92。公司的債務與股本比率為 0.55，速動比率為 1.23，流動比率為 1.23。該股票的 50 日簡單移動平均線為 $6.80，200 日簡單移動平均線為 $5.91。</p>
<h2>機構投資者對 Compass Pathways 的看法</h2>
<p>機構投資者和對沖基金最近調整了對該股票的持有。RTW Investments LP 在第四季度將其在 Compass Pathways 的股份增加了 0.6%。RTW Investments LP 目前擁有 8,757,390 股該公司股票，價值 60,426,000 美元，此前在上個季度增持了 50,000 股。Nantahala Capital Management LLC 在第二季度將其在 Compass Pathways 的股份增加了 47.7%。Nantahala Capital Management LLC 目前擁有 4,179,930 股該公司股票，價值 11,704,000 美元，此前在上個季度增持了 1,350,698 股。Millennium Management LLC 在第三季度將其在 Compass Pathways 的股份增加了 39.9%。Millennium Management LLC 目前擁有 2,715,872 股該公司股票，價值 15,562,000 美元，此前在上個季度增持了 774,090 股。多倫多道明銀行在第四季度將其在 Compass Pathways 的持股增加了 152.9%。多倫多道明銀行目前擁有 2,529,013 股該公司股票，價值 17,447,000 美元，此前在上個季度增持了 1,529,013 股。最後，ARK Investment Management LLC 在第四季度將其在 Compass Pathways 的股份增加了 1.6%。ARK Investment Management LLC 目前擁有 2,156,012 股該公司股票，價值 14,876,000 美元，此前在上個季度增持了 34,894 股。機構投資者持有該公司 46.19% 的股份。</p>
<h2>關於 Compass Pathways</h2>
<p>（獲取免費報告）</p>
<p>Compass Pathways NASDAQ: CMPS 是一家臨牀階段的生物技術公司，專注於開發和商業化用於心理健康障礙的迷幻蘑菇療法。公司成立於 2016 年，總部位於倫敦，並在美國設有辦事處，Compass Pathways 正在開創將合成迷幻蘑菇與心理治療相結合的治療方案，以應對難治性抑鬱症。該公司的旗艦項目是一個 IIb 期臨牀試驗，評估其專有的迷幻蘑菇配方 COMP360，該配方已獲得美國的突破性療法認證。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Compass Pathways</li>
<li>你的銀行賬户不再安全</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>這隻 $15 的股票可能會成為 2026 年的第一隻股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Compass Pathways 嗎？</h2>
<p>在你考慮 Compass Pathways 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Compass Pathways 並不在名單上。</p>
<p>雖然 Compass Pathways 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CMPS

<p>Compass Pathways（納斯達克代碼：CMPS）經歷了顯著的交易量增加，交易量達到 7,108,036 股，比前一交易日增長了 155%。該股票目前價格為 7.9980 美元，低於前一交易日的收盤價 8.45 美元。分析師的評級各不相同，其中有一項強烈買入、七項買入、一項持有和一項賣出。共識評級為 “適度買入”，目標價格為 17.56 美元。機構投資者持有該股票的 46.19%，公司專注於用於心理健康障礙的迷幻蘑菇治療</p>

<p>Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) saw strong trading volume on Thursday . 7,108,036 shares were traded during trading, an increase of 155% from the previous session's volume of 2,787,246 shares.The stock last traded at $7.9980 and had previously closed at $8.45.</p>
<div class="lb-trans"><p>Compass Pathways PLC 贊助的 ADR（NASDAQ:CMPS - 獲取免費報告）在週四的交易中交易量強勁。當天交易了 7,108,036 股，較前一交易日的 2,787,246 股增加了 155%。該股票最後交易價格為 $7.9980，之前收盤價為 $8.45。</p>
</div><p>Get <strong>Compass Pathways</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Compass Pathways</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><ul>
<li>Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise</li>
</ul>
<div class="lb-trans"><ul>
<li>魔法蘑菇，現金：Compass Pathways 的試驗勝利，快速融資</li>
</ul>
</div><p>CMPS has been the subject of several analyst reports. Lifesci Capital upgraded shares of Compass Pathways to a &#34;strong-buy&#34; rating in a research note on Thursday, February 12th. Compass Point set a $15.00 price objective on Compass Pathways in a research report on Thursday, February 12th. Morgan Stanley boosted their target price on Compass Pathways from $11.00 to $18.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday. Canaccord Genuity Group raised their price target on Compass Pathways from $15.00 to $20.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Compass Pathways in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $17.56.</p>
<div class="lb-trans"><p>CMPS 已成為多份分析師報告的主題。Lifesci Capital 在 2 月 12 日的研究報告中將 Compass Pathways 的股票評級上調至 &#34;強力買入&#34;。Compass Point 在 2 月 12 日的研究報告中設定了 Compass Pathways 的目標價為 $15.00。摩根士丹利在週三的研究報告中將 Compass Pathways 的目標價從 $11.00 提升至 $18.00，並給予該股票 &#34;超配&#34; 的評級。Canaccord Genuity Group 在週三的報告中將 Compass Pathways 的目標價從 $15.00 提升至 $20.00，並給予該公司 &#34;買入&#34; 的評級。最後，Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Compass Pathways 股票的 &#34;賣出（d-）&#34; 評級。一位分析師給予該股票 &#34;強力買入&#34; 的評級，七位分析師給予 &#34;買入&#34; 評級，一位分析師給予 &#34;持有&#34; 評級，一位分析師給予 &#34;賣出&#34; 評級。根據 MarketBeat 的數據，該公司的共識評級為 &#34;適度買入&#34;，共識目標價為 $17.56。</p>
</div><p><strong>Read Our Latest Report on CMPS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CMPS 的最新報告</strong></p>
</div><h2>Compass Pathways Trading Down 3.3%</h2>
<div class="lb-trans"><h2>Compass Pathways 股價下跌 3.3%</h2>
</div><p>The firm has a market cap of $784.20 million, a P/E ratio of -3.01 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The stock has a fifty day simple moving average of $6.80 and a 200 day simple moving average of $5.91.</p>
<div class="lb-trans"><p>該公司的市值為 7.842 億美元，市盈率為 -3.01，貝塔係數為 1.92。公司的債務與股本比率為 0.55，速動比率為 1.23，流動比率為 1.23。該股票的 50 日簡單移動平均線為 $6.80，200 日簡單移動平均線為 $5.91。</p>
</div><h2>Institutional Investors Weigh In On Compass Pathways</h2>
<div class="lb-trans"><h2>機構投資者對 Compass Pathways 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP grew its stake in Compass Pathways by 0.6% during the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company's stock valued at $60,426,000 after acquiring an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC lifted its position in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company's stock worth $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Millennium Management LLC increased its stake in Compass Pathways by 39.9% in the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company's stock worth $15,562,000 after acquiring an additional 774,090 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company's stock valued at $17,447,000 after purchasing an additional 1,529,013 shares in the last quarter. Finally, ARK Investment Management LLC raised its stake in Compass Pathways by 1.6% during the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company's stock valued at $14,876,000 after purchasing an additional 34,894 shares in the last quarter. Institutional investors own 46.19% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該股票的持有。RTW Investments LP 在第四季度將其在 Compass Pathways 的股份增加了 0.6%。RTW Investments LP 目前擁有 8,757,390 股該公司股票，價值 60,426,000 美元，此前在上個季度增持了 50,000 股。Nantahala Capital Management LLC 在第二季度將其在 Compass Pathways 的股份增加了 47.7%。Nantahala Capital Management LLC 目前擁有 4,179,930 股該公司股票，價值 11,704,000 美元，此前在上個季度增持了 1,350,698 股。Millennium Management LLC 在第三季度將其在 Compass Pathways 的股份增加了 39.9%。Millennium Management LLC 目前擁有 2,715,872 股該公司股票，價值 15,562,000 美元，此前在上個季度增持了 774,090 股。多倫多道明銀行在第四季度將其在 Compass Pathways 的持股增加了 152.9%。多倫多道明銀行目前擁有 2,529,013 股該公司股票，價值 17,447,000 美元，此前在上個季度增持了 1,529,013 股。最後，ARK Investment Management LLC 在第四季度將其在 Compass Pathways 的股份增加了 1.6%。ARK Investment Management LLC 目前擁有 2,156,012 股該公司股票，價值 14,876,000 美元，此前在上個季度增持了 34,894 股。機構投資者持有該公司 46.19% 的股份。</p>
</div><h2>About Compass Pathways</h2>
<div class="lb-trans"><h2>關於 Compass Pathways</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.</p>
<div class="lb-trans"><p>Compass Pathways NASDAQ: CMPS 是一家臨牀階段的生物技術公司，專注於開發和商業化用於心理健康障礙的迷幻蘑菇療法。公司成立於 2016 年，總部位於倫敦，並在美國設有辦事處，Compass Pathways 正在開創將合成迷幻蘑菇與心理治療相結合的治療方案，以應對難治性抑鬱症。該公司的旗艦項目是一個 IIb 期臨牀試驗，評估其專有的迷幻蘑菇配方 COMP360，該配方已獲得美國的突破性療法認證。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Compass Pathways</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Compass Pathways</li>
<li>你的銀行賬户不再安全</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>這隻 $15 的股票可能會成為 2026 年的第一隻股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Pathways Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Compass Pathways 嗎？</h2>
</div><p>Before you consider Compass Pathways, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Compass Pathways 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Compass Pathways 並不在名單上。</p>
</div><p>While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Compass Pathways 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Compass Pathways（納斯達克代碼：CMPS）出現異常高的交易量 - 接下來會發生什麼？